Clinical Trial Update: Sacituzumab Govitecan and Intrathecal Chemotherapy for Treating Leptomeningeal Metastases From Her2-negative Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial assessing Sacituzumab Govitecan in combination with intrathecal chemotherapy for leptomeningeal metastases from HER2-negative breast …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Leptomeningeal Metastases

Drugs mentioned

• Sacituzumab Govitecan (sacituzumab govitecan)

Snippet

Sponsor: Guangzhou Medical University | Conditions: Leptomeningeal Metastases | Phase 1, Phase 2 | Status: RECRUITING